Safety data for known adverse drug reactions with elexacaftor–tezacaftor–ivacaftor (eg, increased alanine aminotransferase or aspartate aminotransferase and rash), possible risks associated with elexacaftor–tezacaftor–ivacaftor (eg, cataracts), and events that are common in individuals with cystic fibrosis (eg, neuropsychiatric events) were additionally reviewed. This evidence concerns the gene GPT and cataract.